Literature DB >> 16227246

A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector.

Jean Publicover1, Elizabeth Ramsburg, John K Rose.   

Abstract

Live attenuated vaccine vectors based on recombinant vesicular stomatitis virus (VSV) are effective in several viral disease models. In this study, we asked if a VSV vector capable of only a single cycle of replication might be an effective alternative to replication-competent VSV vectors. We compared the cellular immune responses to human immunodeficiency virus (HIV) envelope protein (Env) expressed by replication-competent and single-cycle VSV vectors and also examined the antibody response to Env. The single-cycle vector was grown by complementation with VSV G protein and then tested initially for immunogenicity when given by four different routes. When given by the intramuscular route in mice, we found that the single-cycle vector was equivalent to the replication-competent VSV vector in generating high-level primary and memory CD8 T-cell responses as well as antibody responses to Env. Cellular responses were analyzed using major histocompatibility complex class I tetramers and direct measurement of cytotoxic T-lymphocyte activity in vivo. We also found that the recall responses after boosting were equivalent in animals vaccinated with replication-competent or single-cycle vectors. Additionally, we observed recall and heightened memory responses after boosting animals with a single-cycle vector complemented with G protein from a different vesiculovirus. Because expression of HIV Env by G-deleted VSV might allow replication in human cells expressing CD4, we generated a single-cycle VSV recombinant expressing a secreted form of the HIV Env protein. This virus was just as effective as the recombinant expressing the membrane-anchored Env protein at producing CD8 T cells and antibody responses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16227246      PMCID: PMC1262593          DOI: 10.1128/JVI.79.21.13231-13238.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants.

Authors:  N F Rose; P A Marx; A Luckay; D F Nixon; W J Moretto; S M Donahoe; D Montefiori; A Roberts; L Buonocore; J K Rose
Journal:  Cell       Date:  2001-09-07       Impact factor: 41.582

Review 2.  Alphavirus replicon particles as candidate HIV vaccines.

Authors:  Nancy L Davis; Ande West; Elizabeth Reap; Gene MacDonald; Martha Collier; Sergey Dryga; Maureen Maughan; Mary Connell; Chris Walker; Kathryn McGrath; Chad Cecil; Li-Hua Ping; Jeff Frelinger; Robert Olmsted; Paula Keith; Ronald Swanstrom; Carolyn Williamson; Philip Johnson; David Montefiori; Robert E Johnston
Journal:  IUBMB Life       Date:  2002 Apr-May       Impact factor: 3.885

3.  Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.

Authors:  Michael A Egan; Siew Yen Chong; Nina F Rose; Shakuntala Megati; Kevin J Lopez; Eva B Schadeck; J Erik Johnson; Amjed Masood; Priscilla Piacente; Robert E Druilhet; Paul W Barras; Dana L Hasselschwert; Patricia Reilly; Eric M Mishkin; David C Montefiori; Mark G Lewis; David K Clarke; R Michael Hendry; Preston A Marx; John H Eldridge; Stephen A Udem; Zimra R Israel; John K Rose
Journal:  AIDS Res Hum Retroviruses       Date:  2004-09       Impact factor: 2.205

4.  Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies.

Authors:  B Schlereth; J K Rose; L Buonocore; V ter Meulen; S Niewiesk
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

5.  Analysis of the molecules involved in human T-cell leukaemia virus type 1 entry by a vesicular stomatitis virus pseudotype bearing its envelope glycoproteins.

Authors:  Kazu Okuma; Yoshiharu Matsuura; Hironobu Tatsuo; Yoshio Inagaki; Minoru Nakamura; Naoki Yamamoto; Yusuke Yanagi
Journal:  J Gen Virol       Date:  2001-04       Impact factor: 3.891

6.  High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses.

Authors:  Karl Haglund; Ingrid Leiner; Kristen Kerksiek; Linda Buonocore; Eric Pamer; John K Rose
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

7.  Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1.

Authors:  Richard M Coles; Scott N Mueller; William R Heath; Francis R Carbone; Andrew G Brooks
Journal:  J Immunol       Date:  2002-01-15       Impact factor: 5.422

8.  Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease.

Authors:  Jon D Reuter; Beatriz E Vivas-Gonzalez; Daniel Gomez; Jean H Wilson; Janet L Brandsma; Heather L Greenstone; John K Rose; Anjeanette Roberts
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.

Authors:  J S Kahn; A Roberts; C Weibel; L Buonocore; J K Rose
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins.

Authors:  Karl Haglund; Ingrid Leiner; Kristen Kerksiek; Linda Buonocore; Eric Pamer; John K Rose
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

View more
  47 in total

1.  Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine.

Authors:  Sunil Kannanganat; Pragati Nigam; Vijayakumar Velu; Patricia L Earl; Lilin Lai; Lakshmi Chennareddi; Benton Lawson; Robert L Wilson; David C Montefiori; Pamela A Kozlowski; Bernard Moss; Harriet L Robinson; Rama Rao Amara
Journal:  J Immunol       Date:  2010-11-12       Impact factor: 5.422

2.  A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose.

Authors:  Melissa A Cobleigh; Linda Buonocore; Susan L Uprichard; John K Rose; Michael D Robek
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

3.  Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.

Authors:  Guido Wollmann; Eugene Drokhlyansky; John N Davis; Connie Cepko; Anthony N van den Pol
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

4.  Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine.

Authors:  Kathleen M Daddario-DiCaprio; Thomas W Geisbert; Joan B Geisbert; Ute Ströher; Lisa E Hensley; Allen Grolla; Elizabeth A Fritz; Friederike Feldmann; Heinz Feldmann; Steven M Jones
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

5.  Multiple immunizations with adenovirus and MVA vectors improve CD8+ T cell functionality and mucosal homing.

Authors:  Nia Tatsis; Shih-Wen Lin; Kimberly Harris-McCoy; David A Garber; Mark B Feinberg; Hildegund C J Ertl
Journal:  Virology       Date:  2007-06-27       Impact factor: 3.616

6.  Peripheral, but not central nervous system, type I interferon expression in mice in response to intranasal vesicular stomatitis virus infection.

Authors:  Mark D Trottier; Douglas S Lyles; Carol Shoshkes Reiss
Journal:  J Neurovirol       Date:  2007-10       Impact factor: 2.643

7.  Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells.

Authors:  Guido Wollmann; Vitaliy Rogulin; Ian Simon; John K Rose; Anthony N van den Pol
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

8.  Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.

Authors:  Cassandra L Braxton; Shelby H Puckett; Steven B Mizel; Douglas S Lyles
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

9.  Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection.

Authors:  Ming Zhang; Chunsheng Dong; Sidong Xiong
Journal:  Hum Vaccin Immunother       Date:  2016-12-14       Impact factor: 3.452

10.  Characterization of a single-cycle rabies virus-based vaccine vector.

Authors:  Emily A Gomme; Elizabeth J Faul; Phyllis Flomenberg; James P McGettigan; Matthias J Schnell
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.